

Ce(SO₄)₂-Catalysed the Highly Diastereoselective Synthesis of Tetrahydroquinolines Via imino Diels Alder ABB' Type Reaction and their In Vivo Toxicity and Imaging in Zebrafish Embryos

Carlos A. Martínez Bonilla, Carlos E. Puerto Galvis, Leonor Y. Vargas Méndez and Vladimir V. Kouznetsov*

Laboratorio de Química Orgánica y Biomolecular, Universidad Industrial de Santander, Parque Tecnológico Guatiguara, Km 2 via refugio, Piedecuesta, A.A. 681011, Colombia.

** kouznet@uis.edu.co; vkuznechnik@gmail.com.*

ELECTRONIC SUPPORTING INFORMATION

List of contents	Pages
1. Reagents.	ESI-2
2. Characterization data of all synthesized 2-methyltetrahydroquinolines 3a-l .	ESI-2
3. Copies of ¹ H NMR, ¹³ C NMR, DEPT-135, COSY, HSQC and HMBC charts of the synthesized 2-methyltetrahydroquinolines 3a-l .	ESI-10
4. Photographic records of the phenotypic changes during the development of the zebrafish embryos treated with compounds 3a-l after 96 hpf.	ESI-42

1. Reagents

Aniline: Was purchased from Merck and used as received.

4'-Aminoacetanilide: Was purchased from Merck and used as received.

p-Anisidine: Was purchased from Aldrich and used as received.

4-Aminobenzoic acid: Was purchased from Aldrich and used as received.

N-Vinylacetamide: Was purchased from Aldrich and used as received.

N-Vinylformamide: Was purchased from Aldrich and used as received.

1-Vinyl-2-pyrrolidone: Was purchased from Merck and used as received.

Ceric ammonium nitrate: Was purchased from Merck and used as received.

Cerium(IV) sulfate: Was purchased from Merck and used as received.

Methanol: Was purchased from Merck and used as received.

Acetonitrile: Was purchased from J.T.Baker and used as received.

Dimethyl sulfoxide: Was purchased from Aldrich and used as received.

Silica gel 60 (0.063-0.200 mm) 70-230 mesh: Was purchased from Merck and used as received.

2. Characterization data of all synthesized 2-methyltetrahydroquinolines 3a-l

cis-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline (3a): White solid (0.43 g, 1.78 mmol, 89 %), R_f [hexane-EtOAc] = 0.5; mp: 225-228 °C; FT-IR (KBr disk, cm⁻¹): 3363, 3239, 3070, 1635, 1589, 1434, 1280, 817; ¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 8.18 (d, J = 8.8 Hz, 1H, 4-NH), 7.55 (d, J = 8.3 Hz, 1H, 7-H_{Ar}), 7.52 (s, 1H, 5-H_{Ar}), 6.73 (s, 1H, 1-NH), 6.48 (d, J = 8.3 Hz, 1H, 8-H_{Ar}), 5.02 (ddd, J = 11.5, 8.8, 5.4 Hz, 1H, 4-H_{ax}), 3.55 (dq, J = 11.5, 6.3, 2.6 Hz, 1H, 2-H_{ax}), 2.35 (s, 3H, 6-COCH₃), 2.02-1.96 (m, 1H, 3-H_{eq}), 1.94 (s, 3H, 4-COCH₃), 1.38 (q, J = 11.5 Hz, 1H, 3-H_{ax}), 1.17 (d, J = 6.3 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ(ppm): 194.9, 169.4, 149.9, 129.3 (+), 127.2 (+), 124.4, 120.2, 112.0 (+), 45.9 (+), 44.9 (+), 36.6 (-), 25.8 (+), 22.8 (+), 21.5 (+); COSY correlation [δ_H/δ_H]: 1.17/3.55 [2-CH₃/2-H_{ax}], 1.38/5.02/2.02-1.96 [3-H_{ax}/4-H_{ax}/3-H_{eq}], 2.02-1.96/5.02/1.38 [3-H_{eq}/4-H_{ax}/3-H_{ax}], 3.55/2.02-1.96/1.38/1.17 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.02/2.02-1.96/1.38 [4-H_{ax}/3-H_{eq}/3-H_{ax}], 6.48/7.55 [8-H_{Ar}/7-H_{Ar}], 7.55/6.48 [7-H_{Ar}/8-H_{Ar}], 8.18/5.02 [4-NH/4-H_{ax}]; HSQC correlation [δ_H/δ_C]: 1.17/21.5 [2-CH₃/C-11], 1.38/36.6 [3-H_{ax}/C-3], 1.94/22.8 [4-COCH₃/C-14], 2.02-1.96/36.6 [3-H_{eq}/C-3], 2.35/25.8 [6-COCH₃/C-16], 3.55/46.0 [2-H_{ax}/C-2], 5.02/44.9 [4-H_{ax}/C-4], 6.48/112.0 [8-H_{Ar}/C-8], 7.52/127.2 [5-H_{Ar}/C-5], 7.55/129.3 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.17/46.0/36.6 [2-CH₃/C-2/C-3], 1.38/46.0/44.9/21.5 [3-H_{ax}/C-2/C-4/C-11], 1.94/169.4 [4-COCH₃/C-13], 2.02-1.96/44.9 [3-H_{eq}/C-4], 2.35/194.7/124.4 [6-COCH₃/C-12/C-6], 5.02/36.6/120.2 [4-H_{ax}/C-3/C-9], 6.48/124.4/120.2/44.9 [8-H_{Ar}/C-6/C-9/C-4], 6.73/149.9/120.2/112.0/46.0/36.6/21.5 [1-NH/C-10/C-9/C-8/C-2/C-3/C-11], 7.52/194.7/149.9/129.3/44.9 [5-H_{Ar}/C-12/C-10/C-7/C-4], 7.55/194.7/149.9/127.2 [7-H_{Ar}/C-12/C-10/C-5], 8.18/169.4/44.9 [4-NH/C-13/C-4]; GC: R_t = 24.3 min, MS (EI), m/z (%): 246 (M⁺, 5),

231 (5), 215 (2), 203 (12), 186 (80), 172 (100), 77 (3); HRMS (ESI+): m/z : calcd for C₁₄H₁₉N₂O₂ ([M+H]⁺) 247,1441, found: 247,1437; calcd for C₁₄H₁₈N₂NaO₂ ([M+Na]⁺) 269,1260, found: 269,1263.

cis-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline (3b): White solid (0.33 g, 1.6 mmol, 80 %), R_f [hexane-EtOAc 1:1] = 0.7; mp: 170-172 °C; FT-IR (KBr disk, cm⁻¹): 3347, 3255, 3070, 2962, 1635, 1496, 1311, 971, 755; ¹H NMR (400 MHz, CDCl₃), δ (ppm): 8.12 (d, J = 8.9 Hz, 1H, 4-NH), 6.92-6.86 (m, 2H, 8-H_{Ar}), 6.49-6.44 (m, 2H, 7-H_{Ar} and 5-H_{Ar}), 5.66 (s, 1H, 1-NH), 5.02 (ddd, J = 11.8, 8.9, 6.0 Hz, 1H, 4-H_{ax}), 3.44-3.38 (m, 1H, 2-H_{ax}), 1.95-1.89 (m, 1H, 2-H_{ax}), 1.88 (s, 3H, 4-COCH₃), 1.38 (q, J = 11.8 Hz, 1H, 3-H_{ax}), 1.12 (d, J = 6.2 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, CDCl₃), δ (ppm): 169.2, 145.7, 127.4 (+), 126.6 (+), 121.3, 115.5 (+), 113.4 (+), 46.1 (+), 45.2 (+), 37.5 (-), 22.8 (+), 22.0 (+); COSY correlation [δ_H/δ_H]: 1.12/3.44-3.38 [2-CH₃/2-H_{ax}], 1.38/5.02/3.44-3.38/1.95-1.89 [3-H_{ax}/4-H_{ax}/2-H_{ax}/3-H_{eq}], 1.95-1.89/5.02/3.44-3.38/1.38 [3-H_{eq}/4-H_{ax}/2-H_{ax}/3-H_{ax}], 3.44-3.38/1.95-1.89/1.38/1.12 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.02/8.12/1.95/1.38-1.89 [4-H_{ax}/4-NH/3-H_{ax}/3-H_{eq}], 8.12/5.02 [4-NH/4-H_{ax}]; HSQC correlation [δ_H/δ_C]: 1.12/22.0 [2-CH₃/C-11], 1.38/37.5 [3-H_{ax}/C-3], 1.88/22.8 [4-COCH₃/C-14], 1.95-1.89/37.5 [3-H_{eq}/C-3], 3.44-3.38/46.1 [2-H_{ax}/C-2], 5.02/45.7 [4-H_{ax}/C-4], 6.49-6.44/113.4,115.5 [7-H_{Ar},5-H_{Ar}/C-5,C-7], 6.92-6.86/127.4,126.7 [6-H_{Ar},8-H_{Ar}/C-8,C-6]; HMBC correlation [δ_H/δ_C]: 1.12/46.1/37.5 [2-CH₃/C-2/C-3], 1.38/46.1/45.2/22.0 [3-H_{ax}/C-2/C-4/C-11], 1.88/169.2 [4-COCH₃/C-13], 1.95-1.89/121.4/45.2 [3-H_{eq}/C-9/C-4], 5.66/121.4/113.4/37.5 [1-NH/C-9/C-8/C-3], 6.49-6.44/121.4/115.5,113.4 [7-H_{Ar},5-H_{Ar}/C-9/C-6,C-8], 6.92-6.86/127.4,126.6/145.8/45.2 [6-H_{Ar},8-H_{Ar}/C-7,C-5/C-10/C-4], 8.12/169.2 [4-NH/C-13]; GC: R_t = 16.7 min, MS (EI), m/z (%): 204 (M⁺, 25), 187 (2), 173 (2), 161 (5), 114 (60), 130 (100), 77 (5); HRMS (ESI+): m/z : calcd for C₁₂H₁₇N₂O ([M+H]⁺) 205,1335, found: 205,1339; calcd for C₁₂H₁₆N₂NaO ([M+Na]⁺) 227,1155, found: 227,1152.

cis-4-Acetamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline (3c): White solid (0.36 g, 1.54 mmol, 77 %), R_f [hexane-EtOAc 1:1] = 0.7; mp: 176-178 °C; FT-IR (KBr disk, cm⁻¹): 3378, 3286, 2962, 1727, 1635, 1542, 1295, 1234, 1157, 1033, 817; ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): 8.15 (d, 1H, J = 8.7 Hz, 4-NH), 6.58 (d, 1H, J = 8.5 Hz, 7-H_{Ar}), 6.51 (s, 1H, 5-H_{Ar}), 6.43 (d, 1H, J = 8.5 Hz, 8-H_{Ar}), 5.28 (s, 1H, 1-NH), 5.05-4.98 (m, 1H, 4-H_{ax}), 3.60 (s, 3H, 6-OCH₃), 3.30-3.37 (m, 1H, 2-H_{ax}), 1.96-1.90 (m, 1H, 3-H_{eq}), 1.89 (s, 3H, 4-COCH₃), 1.36 (q, 1H, J = 11.7 Hz, 3-H_{ax}), 1.10 (d, 3H, J = 6.0 Hz, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ (ppm): 169.3, 150.7, 140.1, 122.7, 114.6 (+), 113.6 (+), 112.4 (+), 55.4 (+), 46.4 (+), 45.4 (+), 37.7 (-), 22.8 (+), 22.0 (+); GC: R_t = 20.7 min, MS (EI), m/z (%): 234 (M⁺, 25), 234 (25), 219 (2), 203 (2), 174 (55), 160 (100); HRMS (ESI+): m/z : calcd for C₁₃H₁₉N₂O₂ ([M+H]⁺) 235,1441, found: 235,1439; calcd for C₁₃H₁₈N₂NaO₂ ([M+Na]⁺) 257,1260, found: 257,1261.

cis-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline (3d): White solid (0.37 g, 1.5 mmol, 75 %), R_f [hexane-EtOAc 1:2] = 0.4; mp: 259-262 °C; FT-IR (KBr disk, cm^{-1}): 3363, 3301, 3270, 2962, 2591, 1666, 1604, 1511, 1295, 833, 771; ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 11.9 (br., s, 1H, 6-COOH), 8.21 (d, J = 9.0 Hz, 1H, 4-NH), 7.52 (s, 1H, 5-H_{Ar}), 7.50-7.52 (m, 1H, 7-H_{Ar}), 6.54 (s, 1H, 1-NH), 6.47 (d, J = 9.0 Hz, 1H, 8-H_{Ar}), 5.01 (dd, J = 11.8, 9.0 Hz, 1H, 4-H_{ax}), 3.53 (dq, J = 11.8, 6.3, 2.5 Hz, 1H, 2-H_{ax}), 1.95-1.98 (m, 1H, 3-H_{eq}), 1.93 (s, 3H, 4-COCH₃), 1.38 (q, J = 11.8 Hz, 1H, 3-H_{ax}), 1.16 (d, J = 6.3 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-*d*₆), δ (ppm): 169.5, 167.7, 149.6, 129.7 (+), 128.5 (+), 120.3, 116.5, 112.3 (+), 46.0 (+), 45.0 (+), 36.8 (-), 22.9 (+), 21.6 (+); COSY correlation [δ_H/δ_H]: 1.16/3.53 [2-CH₃/2-H_{ax}], 1.38/5.01/3.53/1.95-1.98 [3-H_{ax}/4-H_{ax}/2-H_{ax}/3-H_{eq}], 1.95-1.98/5.01/3.53/1.38 [3-H_{eq}/4-H_{ax}/2-H_{ax}/3-H_{ax}], 3.53/1.95-1.98/1.38/1.16 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.01/8.21/1.95-1.98/1.38 [4-H_{ax}/4-NH/3-H_{eq}/3-H_{ax}], 6.47/7.50-7.52 [8-H_{Ar}/7-H_{Ar}], 6.54/1.95-1.98 [1-NH/3-H_{eq}], 7.50-7.52/6.47 [7-H_{Ar}/8-H_{Ar}], 7.52/5.01 [5-H_{Ar}/4-H_{ax}], 8.21/5.01 [4-NH/4-H_{ax}]; HSQC correlation [δ_H/δ_C]: 1.16/21.6 [2-CH₃/C-11], 1.93/22.7 [4-COCH₃/C-14], 1.95-1.98/1.4 [3-H_{eq}/3-H_{ax}/C-3], 3.53/46.0 [2-H_{ax}/C-2], 5.01/45.0 [4-H_{ax}/C-4], 6.47/112.3 [8-H_{Ar}/C-8], 7.50-7.52/129.7 [7-H_{Ar}/C-7], 7.52/128.5 [5-H_{Ar}/C-5]; HMBC correlation [δ_H/δ_C]: 1.16/46.0/36.8 [2-CH₃/C-2/C-3], 1.38/46.0/45.0/21.6 [3-H_{ax}/C-2/C-4/C-11], 1.93/169.5 [4-COCH₃/C-13], 1.95-1.98/45.0 [3-H_{eq}/C-4], 5.01/169.5/120.3/36.8 [4-H_{ax}/C-13/C-10/C-3], 6.47/167.7/128.5/120.3/116.5/45.9 [8-H_{Ar}/C-15/C-5/C-10/C-6/C-4], 6.54/149.6/128.5/120.3/112.4/46.0/36.8/21.64 [1-NH/C-9/C-5/C-10/C-8/C-2/C-3/C-11], 7.50-7.52/167.7/149.6/112.3 [7-H_{Ar}/C-15/C-9/C-8], 7.52/167.7/129.7/45.0 [5-H_{Ar}/C-15/C-7/C-4], 8.21/169.5/120.3/45.0/36.8 [4-NH/C-13/C-10/C-4/C-3]; GC: R_t = 17.6 min, MS (EI), m/z (%): 204 (M⁺-44, 5), 161 (5), 144 (60), 130 (100), 77 (10); HRMS (ESI⁺): m/z : calcd for C₁₃H₁₇N₂O₃ ([M+H]⁺) 249,1234, found: 249,1237; calcd for C₁₃H₁₆N₂NaO₃ ([M+Na]⁺) 271,1053, found: 271,1049.

cis-6-Acetyl-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline (3e): Pale yellow solid (0.32 g, 1.38 mmol, 69 %), R_f [hexane-EtOAc 1:1] = 0.5; mp: 235-237 °C; FT-IR (KBr disk, cm^{-1}): 3348, 3255, 3039, 1650, 1589, 1434, 1249, 817; ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 8.28 (d, J = 9.3 Hz, 1H, 4-NH), 8.23 (s, 1H, 4-COH), 7.56 (d, J = 1.3 Hz, 1H, 5-H_{Ar}), 7.51 (dd, J = 8.5, 1.3 Hz, 1H, 7-H_{Ar}), 6.51-6.42 (m, 2H, 1-NH and 8-H_{Ar}), 5.12 (ddd, J = 12.2, 9.3, 4.2 Hz, 1H, 4-H_{ax}), 3.55 (dq, J = 12.2, 6.3, 2.1 Hz, 1H, 2-H_{ax}), 2.35 (s, 3H, 2-H_{ax}), 2.04 (td, J = 12.2, 4.2, 2.1 Hz, 1H, 3-H_{eq}), 1.42 (q, J = 12.2 Hz, 1H, 3-H_{ax}), 1.18 (d, J = 6.3 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-*d*₆), δ (ppm): 194.5, 161.0 (+), 149.6, 128.9 (+), 127.1 (+), 124.4, 119.1, 112.0 (+), 45.8 (+), 43.6 (+), 36.4 (-), 25.5 (+), 21.3 (+); GC: R_t = 24.3 min, MS (EI), m/z (%): 232 (M⁺, 25), 217 (10), 186 (60), 172 (100), 161 (10), 144 (25), 129 (8); HRMS (ESI⁺): m/z : calcd for C₁₃H₁₇N₂O₂ ([M+H]⁺) 233,1285, found: 233,1288; calcd for C₁₃H₁₆N₂NaO₂ ([M+Na]⁺) 255,1104, found: 255,1106.

cis-4-Formamido-2-methyl-1,2,3,4-tetrahydroquinoline (3f): White solid (0.26 g, 1.40 mmol, 70 %), R_f [hexane-EtOAc 1:1] = 0.6; mp: 151-153 °C; FT-IR (KBr disk, cm⁻¹): 3286, 3023, 1666, 1527, 1496, 755; ¹H NMR (400 MHz, CDCl₃), δ (ppm): 8.29 (1H, s, 4-COH), 7.10 (1H, dd, $J = 7.7$, 0.84 Hz, 5-H_{Ar}), 7.03 (1H, td, $J = 7.7$, 7.5, 0.58 Hz, 6-H_{Ar}), 6.67 (1H, td, $J = 7.5$, 0.84 Hz, 7-H_{Ar}), 6.49 (1H, dd, $J = 7.5$, 0.58 Hz, 8-H_{Ar}), 5.87 (1H, d, $J = 8.4$ Hz, 4-NH), 5.39 (1H, ddd, $J = 11.4$, 8.4, 6.2 Hz, 4-H_{ax}), 3.78 (1H, s, 1-NH), 3.53 (1H, dqd, $J = 11.4$, 6.3, 2.1 Hz, 2-H_{ax}), 2.26 (1H, ddd, $J = 11.4$, 6.2, 2.1 Hz, 3-H_{eq}), 1.45 (1H, q, $J = 11.4$ Hz, 3-H_{ax}), 1.20 (3H, d, $J = 6.3$ Hz, 2-CH₃); ¹³C NMR (101 MHz, CDCl₃), δ (ppm): 161.3 (+), 145.3, 128.53 (+), 127.02 (+), 120.87, 117.87 (+), 114.53 (+), 46.69 (+), 44.96 (+), 37.96 (-), 22.20 (+); GC: R_t = 16.7 min, MS (EI), m/z (%): 190 (M⁺, 25), 161 (10), 144 (45), 130 (100), 77 (15); HRMS (ESI⁺): m/z : calcd for C₁₁H₁₅N₂O ([M+H]⁺) 191,1178, found: 191,1182; calcd for C₁₁H₁₄N₂NaO ([M+Na]⁺) 213,0998, found: 213,1001.

cis-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline (3g): White solid (0.28 g, 1.26 mmol, 63 %), R_f [hexane-EtOAc 1:1] = 0.6; mp: 151-153 °C; FT-IR (KBr disk, cm⁻¹): 3286, 3239, 3023, 2838, 1666, 1542, 1265, 1234, 1033, 725; ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): 8.35 (d, $J = 8.4$ Hz, 1H, 4-NH), 8.19 (s, 1H, 4-COH), 6.59 (d, $J = 8.4$ Hz, 1H, 7-H_{Ar}), 6.53 (s, 1H, 5-H_{Ar}), 6.45 (d, $J = 8.4$ Hz, 1H, 8-H_{Ar}), 5.30 (s, 1H, 1-NH), 5.12 (ddd, $J = 11.5$, 8.4, 3.5 Hz, 1H, 4-H_{ax}), 3.60 (s, 3H, 6-OCH₃), 3.36-3.34 (m, 1H, 2-H_{ax}), 1.98-1.94 (m, 1H, 3-H_{eq}), 1.39 (q, $J = 11.5$ Hz, 1H, 3-H_{ax}), 1.11 (d, $J = 5.7$ Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ (ppm): 161.2 (+), 150.7, 140.1, 121.9, 114.8 (+), 114.0 (+), 112.1 (+), 55.4 (+), 46.3 (+), 44.2 (+), 37.6 (-), 22.0 (+); COSY correlation [δ_H/δ_H]: 1.11/3.36-3.34 [2-CH₃/2-H_{ax}], 1.39/3.36-3.34/1.96/5.12 [3-H_{ax}/2-H_{ax}/3-H_{eq}/4-H_{ax}], 1.96/3.36-3.34/1.39/5.12 [3-H_{eq}/2-H_{ax}/3-H_{ax}/4-H_{ax}], 3.36-3.34/1.96/1.39/1.11 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.12/8.35/1.96/1.39 [4-H_{ax}/4-NH/3-H_{eq}/3-H_{ax}], 6.45/6.59 [8-H_{Ar}/7-H_{Ar}], 6.59/6.45 [7-H_{Ar}/8-H_{Ar}], 8.35/5.12 [4-NH/4-H_{ax}]; HSQC correlation [δ_H/δ_C]: 1.11/46.3 [2-CH₃/C-11], 1.39/37.6 [3-H_{ax}/C-3], 1.96/37.6 [3-H_{eq}/C-3], 3.36-3.34/46.3 [2-H_{ax}/C-2], 3.60/55.4 [6-OCH₃/C-15], 5.12/44.2 [4-H_{ax}/C-4], 6.45/114.8 [8-H_{Ar}/C-8], 6.53/112.1 [5-H_{Ar}/C-5], 6.59/114.0 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.11/46.3/37.6 [2-CH₃/C-2/C-3], 1.39/121.8/46.3/44.2/22.0 [3-H_{ax}/C-9/C-2/C-4/C-11], 1.96/121.8/44.2 [3-H_{eq}/C-9/C-4], 3.60/150.7 [6-OCH₃/C-6], 5.12/161.2/121.8/37.9 [4-H_{ax}/C-13/C-9/C-3], 5.30/121.8/114.8/37.6/22.0 [1-NH/C-9/C-8/C-3/C-11], 6.45/150.7/121.8/112.1/44.2 [8-H_{Ar}/C-6/C-9/C-5/C-4], 6.53/150.7/140.1/114.0/44.2 [5-H_{Ar}/C-6/C-10/C-7/C-4], 6.59/150.7/140.1/112.1 [7-H_{Ar}/C-6/C-10/C-5], 8.19/44.2 [4-COH/C-4], 8.3/161.2/44.2 [4-NH/C-13/C-4]; GC: R_t = 20.4 min, MS (EI), m/z (%): 220 (M⁺, 35), 160 (100), 145 (10), 130 (15), 117 (15); HRMS (ESI⁺): m/z : calcd for C₁₂H₁₇N₂O₂ ([M+H]⁺) 221,1285, found: 221,1282; calcd for C₁₂H₁₆N₂NaO₂ ([M+Na]⁺) 243,1104, found: 243,1101.

cis-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline (3h): White solid (0.38 g, 1.62 mmol, 81 %), R_f [hexane-EtOAc 1:2] = 0.4; mp: 208-210 °C; FT-IR (KBr disk, cm⁻¹): 3394, 2962, 2653, 2561, 1666, 1604, 1527, 1419, 1280, 1172, 833, 771; ¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 12.05 (br., s, 1H, 6-COOH), 8.41 (d, J = 8.9 Hz, 1H, 4-NH), 8.25 (s, 1H, 4-COH), 7.53 (s, 1H, 5-H_{Ar}), 7.50-7.52 (m, 1H, 7-H_{Ar}), 6.57 (s, 1H, 1-NH), 6.48 (d, J = 8.3 Hz, 1H, 8-H_{Ar}), 5.11 (ddd, J = 11.8, 8.9, 6.5 Hz, 1H, 4-H_{ax}), 3.59-3.51 (m, 1H, 2-H_{ax}), 2.02-1.93 (m, 1H, 3-H_{eq}), 1.41 (q, J = 11.8 Hz, 1H, 3-H_{ax}), 1.17 (d, J = 6.1 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ(ppm): 167.6, 161.3 (+), 149.5, 129.8 (+), 128.5 (+), 119.5, 116.7, 112.4 (+), 45.9 (+), 43.6 (+), 36.5 (-), 21.5 (+); COSY correlation [δ_H/δ_H]: 1.17/3.59-3.51 [2-CH₃/2-H_{ax}], 1.41/5.11/3.59-3.51/2.02-1.93 [3-H_{ax}/4-H_{ax}/2-H_{ax}/3-H_{eq}], 2.02-1.93/5.11/3.59-3.51/1.41 [3-H_{eq}/4-H_{ax}/2-H_{ax}/3-H_{ax}], 3.59-3.51/2.02-1.93/1.41/1.17 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.11/8.41/1.93-2.02/1.41 [4-H_{ax}/4-NH/3-H_{eq}/3-H_{ax}], 7.50-7.52/6.48 [7-H_{Ar}/8-H_{Ar}], 8.41/5.11 [4-NH/4-H_{ax}]; HSQC correlation [δ_H/δ_C]: 1.17/21.5 [2-CH₃/C-11], 2.02-1.9/1.41/36.5 [3-H_{eq}/3-H_{ax}/C-3], 3.59-3.51/45.9 [2-H_{ax}/C-2], 5.11/43.6 [4-H_{ax}/C-4], 6.48/112.4 [8-H_{Ar}/C-8], 7.50-7.52/129.8 [7-H_{Ar}/C-7], 7.53/128.5 [5-H_{Ar}/C-5], 8.25/161.3 [4-COH/C-13]; HMBC correlation [δ_H/δ_C]: 1.17/36.5/45.9 [2-CH₃/C-3/C-2], 1.41/45.9/43.6/21.5 [3-H_{ax}/C-2/C-4/C-11], 2.02-1.93/43.6/119.5 [3-H_{eq}/C-4/C-9], 5.11/36.6 [4-H_{ax}/C-3], 6.48/119.5/116.7 [8-H_{Ar}/C-9/C-6], 6.57/149.5/119.5/112.4/45.9/36.5/21.5 [1-NH/C-10/C-9/C-8/C-2/C-3/C-11], 7.50-7.52/167.6/149.5/128.5/112.4 [7-H_{Ar}/C-14/C-10/C-5/C-8], 7.53/149.5/129.8/43.6 [5-H_{Ar}/C-10/C-7/C-4], 8.25/43.6 [4-COH/C-4], 8.41/161.3/43.6/36.5 [4-NH/C-13/C-4/C-3]; GC: R_t = 23.3 min, MS (EI), m/z (%): 190 (M⁺-44, 30), 161 (5) 145 (63), 130 (100), 103 (5), 77 (15); HRMS (ESI⁺): m/z : calcd for C₁₂H₁₅N₂O₃ ([M+H]⁺) 235,1077, found: 235,1081; calcd for C₁₂H₁₄N₂NaO₃ ([M+Na]⁺) 257,0897, found: 257,0897.

cis-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline (3i): White solid (0.44 g, 1.62 mmol, 81 %), R_f [hexane-EtOAc 1:1] = 0.5; mp: 165-167 °C; FT-IR (KBr disk, cm⁻¹): 3332, 2962, 2915, 2885, 1681, 1573, 1434, 956, 833; ¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 7.57 (dd, J = 8.5, 1.7 Hz, 1H, 7-H_{Ar}), 7.21 (s, 1H, 5-H_{Ar}), 6.77 (s, 1H, 1-NH), 6.53 (d, J = 8.5 Hz, 1H, 8-H_{Ar}), 5.25 (dd, J = 11.9, 5.2 Hz, 1H, 4-H_{ax}), 3.61 (ddd, J = 11.9, 6.3, 2.3 Hz, 1H, 2-H_{ax}), 3.26-3.19 (m, 1H, 5'-H_b), 3.03-2.96 (m, 1H, 5'-H_a), 2.41-2.34 (m, 2H, 3'-H_a and 3'-H_b), 2.36 (s, 3H, 6-COCH₃), 2.02-1.89 (m, 2H, 4'-H_a and 4'-H_b), 1.81 (ddd, J = 11.9, 5.2, 2.3 Hz, 1H, 3-H_{eq}), 1.63 (q, J = 11.9 Hz, 1H, 3-H_{ax}), 1.19 (d, J = 6.3 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ(ppm): 194.9, 174.8, 150.6, 129.5 (+), 126.3 (+), 124.6, 116.8, 112.5 (+), 47.2 (+), 46.0 (+), 41.7 (+), 39.5 (-), 33.1 (-), 30.8 (-), 25.9 (+), 21.4 (+), 18.1 (-); NOESY correlation [δ_H/δ_H]: 1.81/1.63 [3-H_{eq}/3-H_{ax}], 3.03-2.96/2.02-1.89 [5'-H_a/4'-H_a and 4'-H_b], 3.26-3.19/2.02-1.89 [5'-H_b, 4'-H_a and 4'-H_b], 3.61/1.19/1.63 [2-H_{ax}/2-CH₃/3-H_{ax}], 5.25/1.63/1.81 [4-H_{ax}/3-H_{ax}/3-H_{eq}], 7.57/6.53 [7-H_{Ar}/8-H_{Ar}]; COSY correlation [δ_H/δ_H]: 1.19/3.61 [2-CH₃/2-H_{ax}], 1.63/5.25/3.61/1.81 [3-H_{ax}/4-H_{ax}/2-H_{ax}/3-H_{eq}], 1.81/5.25/3.61/1.63 [3-H_{eq}/4-H_{ax}/2-H_{ax}/3-H_{ax}], 2.02-

1.89/3.26-3.19/3.03-2.96/2.41-2.34 [4'-H_a,4'-H_b/5'-H_b/5'-H_a/3'-H_a,3'-H_b], 2.41-2.34/2.02-1.89 [3'-H_a,3'-H_b/4'-H_a,4'-H_b], 3.03-2.96/3.26-3.19/2.02-1.89 [5'-H_a/5'-H_b/4'-H_a,4'-H_b], 3.26-3.19/3.03-2.96/2.02-1.89 [5'-H_b/5'-H_a/4'-H_a,4'-H_b], 3.61/1.81/1.63/1.19 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.25/1.81/1.63 [4-H_{ax}/3-H_{eq}/3-H_{ax}], 6.53/7.57 [8-H_{Ar}/7-H_{Ar}], 7.21/7.57 [5-H_{Ar}/7-H_{Ar}], 7.57/7.21/6.53 [7-H_{Ar}/5-H_{Ar}/8-H_{Ar}]; HSQC correlation [δ_H/δ_C]: 1.19/21.4 [2-CH₃/C-11], 1.81/1.63/33.1 [3-H_{eq}/3-H_{ax}/C-3], 2.02-1.89/18.1 [4'-H_a,4'-H_b/C-15], 2.36/25.9 [6-COCH₃/C-18], 3.26-3.19, 3.03-2.96/41.7 [5'-H_b, 5'-H_a/C-16], 3.61/46.0 [2-H_{ax}/C-2], 5.25/47.2 [4-H_{ax}/C-4], 6.53/112.5 [8-H_{Ar}/C-8], 7.21/126.3 [5-H_{Ar}/C-5], 7.57/129.5 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.19/47.2/46.0/33.1/30.8 [2-CH₃/C-4/C-2/C-3/C-14], 1.63/47.2/46.0/21.4 [3-H_{ax}/C-4/C-2/C-11], 1.81/47.2/46.0 [3-H_{eq}/C-4/C-2], 2.02-1.89/174.8/41.7/30.8 [4'-H_a,4'-H_b/C-13/C-16/C-14], 2.36/194.9 [6-COCH₃/C-17], 2.41-2.34/174.8/41.7/18.1 [3'-H_a,3'-H_b/C-13/C-16/C-15], 3.26-3.19,3.03-2.96/174.8/30.8/18.1 [5'-H_b,5'-H_a/C-13/C-14/C-15], 5.25/174.8 /116.8/41.7/33.1 [4-H_{ax}/C-13/C-9/C-16/C-3], 6.53/124.6/116.8/47.2 [8-H_{Ar}/C-10/C-9/C4], 6.77/116.8/112.5/46.0/33.1/21.4 [1-NH/C-9/C-8/C-2/C-3/C-11], 7.21/194.9/150.6/129.6 /47.2 [5-H_{Ar}/C-17/C-6/C-7/C-4], 7.57/194.9/150.6/126.3 [7-H_{Ar}/C-17/C-6/C-5]; GC: *R*_t = 23.6 min, MS (EI), *m/z* (%): 272 (M⁺,5), 257 (3), 243(3), 187 (65), 172 (100); HRMS (ESI⁺): *m/z*: calcd for C₁₆H₂₁N₂O₂ ([M+H]⁺) 273,1598, found: 273,1601; calcd for C₁₆H₂₀N₂NaO₂ ([M+Na]⁺) 295,1417, found: 295,1419.

cis-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline (3j): White solid (0.32 g, 1.4 mmol, 70 %), *R*_f [hexane-EtOAc 1:1] = 0.6; mp: 190-192 °C; FT-IR (KBr disk, cm⁻¹): 3317, 3039, 2977, 2946, 2885, 1666, 1604, 1496, 1265, 755; ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): 6.91 (td, *J* = 7.5, 7.5, 0.9 Hz, 1H, 7-H_{Ar}), 6.62 (d, *J* = 7.5 Hz, 1H, 5-H_{Ar}), 6.53-6.44 (m, 2H, 6-H_{Ar} and 8-H_{Ar}), 5.72 (s, 1H, 1-NH), 5.27 (dd, *J* = 11.8, 5.7 Hz, 1H, 4-H_{ax}), 3.48 (dq, *J* = 11.8, 6.2, 2.1 Hz, 1H, 2-H_{ax}), 3.19 (dt, *J* = 9.4, 7.2 Hz, 1H, 5'-H_b), 2.95 (dt, *J* = 9.4, 6.7 Hz, 1H, 5'-H_a), 2.42-2.26 (m, 2H, 3'-H_a and 3'-H_b), 1.96-1.87 (m, 2H, 4'-H_a and 4'-H_b), 1.75 (ddd, *J* = 11.8, 5.7, 2.1 Hz, 1H, 3-H_{eq}), 1.62 (q, *J* = 11.8 Hz, 1H, 3-H_{ax}), 1.15 (d, *J* = 6.2 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ (ppm): 174.7, 146.5, 127.7 (+), 125.8 (+), 117.8, 115.8 (+), 114.0 (+), 47.5 (+), 46.1 (+), 41.6 (-), 33.7 (-), 30.8 (-), 21.9 (+), 17.8 (-); COSY correlation [δ_H/δ_H]: 3.19/2.95/1.96-1.87 [5'-H_b/5'-H_a/3'-H_a, 3'-H_b], 3.48/1.75/1.62/1.15 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.27/1.75/1.62 [4-H_{ax}/3-H_{eq}/3-H_{ax}], 6.91/ 6.53-6.44 [7-H_{Ar}/6-H_{Ar},8-H_{Ar}], HSQC correlation [δ_H/δ_C]: 1.15/21.9 [2-CH₃/C-11], 1.62/33.7 [3-H_{ax}/C-3], 1.75/33.7 [3-H_{eq}/C-3], 1.96-1.87/17.8 [4'-H_a, 4'-H_b/C-15], 2.42-2.26/30.8 [3'-H_a, 3'-H_b/C-14], 2.95/41.6 [5'-H_a/C-16], 3.19/41.6 [5'-H_b/C-16], 3.48/46.1 [2-H_{ax}/C-2], 5.72/47.5 [4-H_{ax}/C-4], 6.53-6.44/115.8,114.0 [6-H_{Ar}, 8-H_{Ar} /C-6, C-8], 6.62/125.8 [5-H_{Ar}/C-5], 6.91/127.7 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.15/146.5/46.1/33.7 [2-CH₃/C-10/C-2/C-3], 1.62/ 117.8/47.5/46.1/21.9 [3-H_{ax}/C-9/C-4/C-2/C-11], 1.75/125.8/117.8/47.5/21.9/17.8 [3-H_{eq}/C-5/C-9/C-4/C-11/C-15], 1.96-1.87/174.7/41.6/33.7/30.8 [4'-H_a,4'-H_b/C-13/C-16/C-3/C-14], 2.42-2.26/174.7/

41.6/17.8 [3'-H_a, 3'-H_b/C-13/C-16/C-15], 2.95/174.7/30.8/17.8 [5'-H_a/C-13/C-14/C-15], 3.19/174.7/30.8/17.8 [5'-H_b/C-13/C-14/C-15], 5.27/117.8/41.6/33.7 [4-H_{ax}/C-9/C-16/C-3], 5.72/117.8/114.9/46.1/33.7/21.9 [1-NH/C-9/C-8/C-2/C-3/C-11], 6.53-6.44/127.6/117.8/115.8/114.0 [6-H_{Ar},8-H_{Ar}/C-7/C-9/C-6/C-8], 6.62/146.5/127.6/47.5 [5-H_{Ar}/C-10/C-7/C-4], 6.91/146.5/125.8/117.8/114.0 [7-H_{Ar}/C-10/C-5/C-9/C-8]; GC: R_t= 21.1 min, MS (EI), *m/z* (%): 230 (M⁺, 8), 201 (4), 144 (52), 130 (100), 77 (10); HRMS (ESI⁺): *m/z*: calcd for C₁₄H₁₉N₂O ([M+H]⁺) 231,1492, found: 231,1495; calcd for C₁₄H₁₈N₂NaO ([M+Na]⁺) 253,1311, found: 253,1311.

cis-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline (3k):

Yellow oil (0.44 gr, 1.68 mmol, 84 %), R_f [hexane-EtOAc 1:1] = 0.7; FT-IR (liquid film, cm⁻¹): 3332, 2962, 1666, 1496, 1434, 1280, 1033, 817; ¹H NMR (400 MHz, DMSO-d₆), δ(ppm): 6.59 (dd, *J* = 8.7, 2.7 Hz, 1H, 7-H_{Ar}), 6.47 (d, *J* = 8.7 Hz, 1H, 8-H_{Ar}), 6.22 (d, *J* = 2.7 Hz, 1H, 5-H_{Ar}), 5.31 (s, 1H, 1-NH), 5.27 (dd, *J* = 11.9, 6.1 Hz, 1H, 4-H_{ax}), 3.59 (s, 3H, 6-OCH₃), 3.42-3.34 (m, 1H, 2-H_{ax}), 3.19 (1H, dt, *J* = 9.6, 7.4 Hz, 5'-H_b), 2.95 (dt, *J* = 9.6, 6.7 Hz, 1H, 5'-H_a), 2.43-2.26 (m, 2H, 3'-H_a and 3'-H_b), 1.96-1.88 (m, 2H, 4'-H_a and 4'-H_b), 1.73 (ddd, 1H, *J* = 11.9, 6.1, 1.80 Hz, 3-H_{eq}), 1.60 (q, *J* = 11.9 Hz, 1H, 3-H_{ax}), 1.13 (d, *J* = 6.2 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ(ppm): 174.7, 150.9, 140.8, 119.2, 115.3 (+), 113.9 (+), 111.2 (+), 55.3 (+), 47.7 (+), 46.5 (+), 41.7 (-), 33.9 (-), 30.8 (-), 21.9 (+), 17.9 (-); COSY correlation [δ_H/δ_H]: 1.13/3.42-3.34 [2-CH₃/2-H_{ax}], 1.60/5.27/1.73 [3-H_{ax}/4-H_{ax}/3-H_{eq}], 1.73/5.27/1.60 [3-H_{eq}/4-H_{ax}/3-H_{ax}], 1.96-1.88/3.23-3.15/2.95/2.43-2.26 [4'-H_a, 4'-H_b/5'-H_b/5'-H_a/3'-H_a, 3'-H_b], 2.43-2.26/1.96-1.88 [3'-H_a, 3'-H_b/4'-H_a, 4'-H_b], 2.95/3.19/1.96-1.88 [5'-H_a/5'-H_b/4'-H_a, 4'-H_b], 3.23-3.15/2.95/1.96-1.88 [5'-H_b/5'-H_a/4'-H_a, 4'-H_b], 3.42-3.34/1.60/1.13 [2-H_{ax}/3-H_{ax}/2-CH₃], 5.27/1.73/1.60 [4-H_{ax}/3-H_{eq}/3-H_{ax}], 6.22/6.59 [5-H_{Ar}/7-H_{Ar}], 6.47/6.59 [8-H_{Ar}/7-H_{Ar}], 6.59/6.47/6.22 [7-H_{Ar}/8-H_{Ar}/5-H_{Ar}]; HSQC correlation [δ_H/δ_C]: 1.13/21.9 [2-CH₃/C-11], 1.73/1.60/33.9 [3-H_{eq}/3-H_{ax}/C-3], 1.96-1.88/17.9 [4'-H_a, 4'-H_b/C-15], 2.43-2.26/30.8 [3'-H_a, 3'-H_b/C-14], 3.23-3.15/2.95/41.7 [5'-H_b/5'-H_a/C-16], 3.42-3.34/46.5 [2-H_{ax}/C-2], 3.59/55.3 [6-OCH₃/C-18], 5.27/47.7 [4-H_{ax}/C-4], 6.22/111.2 [5-H_{Ar}/C-5], 6.47/115.3 [8-H_{Ar}/C-8], 6.59/113.9 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.13/46.5/33.9 [2-CH₃/C-2/C-3], 1.73,1.60/ 47.7/46.5/21.9 [3-H_{eq}, 3-H_{eq}/C-4/C-2/C-11], 1.96-1.88/30.8/41.7/174.7 [4'-H_a, 4'-H_b/C-14/C-16/C-13], 2.43-2.26/17.9/41.7/174.7 [3'-H_a, 3'-H_b/C-15/C-16/C-13], 3.23-3.15,2.95/17.9/30.8/174.7 [5'-H_b, 5'-H_b/C-15/C-14/C-13], 3.59/150.9 [6-OCH₃/C-6], 5.27/174.7/140.7/119.2/111.2/41.7/33.9 [4-H_{ax}/C-13/C-10/C-9/C-5/C-16/C-3], 5.31/119.2/33.9 [1-NH/C-9/C-3], 6.22/47.7/113.9/119.2/140.8/150.9 [5-H_{Ar}/C-4/C-7/C-9/C-10/C-6], 6.47/47.7/111.2/119.2/140.8/150.9 [8-H_{Ar}/C-4/C-5/C-9/C-10/C-6], 6.59/111.2/119.2/140.8/150.9 [7-H_{Ar}/C-5/C-9/C-10/C-6]; GC: R_t= 23.2 min, MS (EI), *m/z* (%): 260 (M⁺, 45), 245 (3), 175 (20), 174 (60), 160 (100), 77 (4); HRMS (ESI⁺): *m/z*: calcd for C₁₅H₂₁N₂O₂ ([M+H]⁺) 261,1598, found: 261,1595; calcd for C₁₅H₂₀N₂NaO₂ ([M+Na]⁺) 283,1417, found: 283,1419.

cis-6-Carboxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline (3l): White solid (0.4 gr, 1.44 mmol, 72 %), R_f [hexane-EtOAc 1:2] = 0.3; mp: 233-237 °C; FT-IR (KBr disk, cm⁻¹): 3347, 2962, 2854, 1697, 1635, 1527, 1326, 1172, 771; ¹H NMR (400 MHz, DMSO-d₆), δ (ppm): 12.04 (s, 1H, 6-COOH), 7.51 (d, 1H, 7-H_{Ar}), 7.22 (s, 1H, 5-H_{Ar}), 6.59 (s, 1H, 1-NH), 6.52 (d, J = 8.4 Hz, 1H, 8-H_{Ar}), 5.25 (dd, J = 12.0, 4.7 Hz, 1H, 4-H_{ax}), 3.62-3.54 (m, 1H, 2-H_{ax}), 3.26-3.19 (m, 1H, 5'-H_b), 2.98 (td, J = 8.3, 4.5 Hz, 1H, 5'-H_a), 2.38-2.34 (m, 2H, 3'-H_a and 3'-H_b), 2.00-1.89 (m, 2H, 4'-H_a and 4'-H_b), 1.79 (ddd, J = 12.0, 4.7, 2.6 Hz, 1H, 3-H_{eq}), 1.63 (q, J = 12.0 Hz, 1H, 3-H_{ax}), 1.18 (d, J = 6.1 Hz, 3H, 2-CH₃); ¹³C NMR (101 MHz, DMSO-d₆), δ (ppm): 174.8, 167.6, 150.2, 129.8 (+), 127.5 (+), 116.8, 112.8 (+), 47.2 (+), 46.0 (+), 41.7 (-), 33.1 (-), 30.8 (-), 21.5, 18.0 (-); COSY correlation [δ_H/δ_H]: 1.18/3.62-3.54 [2-CH₃/2-H_{ax}], 1.63/5.25/3.62-3.54/1.79 [3-H_{ax}/4-H_{ax}/2-H_{ax}/3-H_{eq}], 1.79/5.25/3.62-3.54/1.63 [3-H_{eq}/4-H_{ax}/2-H_{ax}/3-H_{ax}], 2.00-1.89/3.26-3.19/2.98/2.38-2.34 [4'-H_a,4'-H_b/5'-H_b/5'-H_a/3'-H_a, 3'-H_b], 2.38-2.34/2.00-1.89 [3'-H_a,3'-H_b/4'-H_a, 4'-H_b], 2.98/3.26-3.19/2.00-1.89 [5'-H_a/5'-H_b/4'-H_a,4'-H_b], 3.26-3.19/2.98/2.00-1.89 [5'-H_b/5'-H_a/4'-H_a, 4'-H_b], 3.62-3.54/1.79/1.63/1.18 [2-H_{ax}/3-H_{eq}/3-H_{ax}/2-CH₃], 5.25/1.79/1.63 [4-H_{ax}/3-H_{eq}/3-H_{ax}], 6.52/7.51 [8-H_{Ar}/7-H_{Ar}], 7.51/6.52 [7-H_{Ar}/8-H_{Ar}]; HSQC correlation [δ_H/δ_C]: 1.18/21.5 [2-CH₃/C-11], 1.79, 1.63/33.1 [3-H_{eq}, 3-H_{ax}/C-3], 2.00-1.89/18.0 [4'-H_a, 4'-H_b/C-15], 2.38-2.34/30.8 [3'-H_a,3'-H_b/C-14], 3.26-3.19, 2.98/41.7 [5'-H_b, 5'-H_b/C-16], 3.62-3.54/46.0 [2-H_{ax}/C-2], 5.25/47.2 [4-H_{ax}/C-4], 6.52/112.8 [8-H_{Ar}/C-8], 7.22/127.5 [5-H_{Ar}/C-5], 7.51/129.8 [7-H_{Ar}/C-7]; HMBC correlation [δ_H/δ_C]: 1.18/46.0/33.1 [2-CH₃/C-2/C-3], 1.63/46.0/47.2/21.5 [3-H_{ax}/C-2/C-4/C-11], 1.79/47.2/46.0 [3-H_{eq}/C-4/C-2], 2.00-1.89/174.8/41.7/30.8 [4'-H_a,4'-H_b/C-13/C-16/C-14], 2.38-2.34/174.8/41.7/18.0 [3'-H_a,3'-H_b/C-13/C-16/C-15], 3.26-3.19,2.98/174.8/18.0 [5'-H_b,5'-H_a/C-13/C-15], 5.25/116.8/33.1 [4-H_{ax}/C-9/C-3], 6.52/129.8/116.8 [8-H_{Ar}/C-7/C-9], 6.59/116.8/112.8/46.0/33.1/21.5 [1-NH/C-9/C-8/C-2/C-3/C-11], 7.22/167.6/150.2/129.8/47.2 [5-H_{Ar}/C-17/C-6/C-7/C-4], 7.51/167.6/150.2/127.5/112.8 [7-H_{Ar}/C-17/C-6/C-5/C-8]; GC: R_t = 24.9 min, MS (EI), m/z (%): 230 (M⁺-44, 30), 201 (10), 159 (5), 145 (70), 130 (100), 103 (8), 77 (12); HRMS (ESI⁺): m/z : calcd for C₁₅H₁₉N₂O₃ ([M+H]⁺) 275,1390, found: 275,1394; calcd for C₁₅H₁₈N₂NaO₃ ([M+Na]⁺) 297,1210, found: 297,1207.

3. Copies of ¹H NMR, ¹³C NMR, DEPT-135, COSY, HSQC and HMBC charts of the synthesized 2-methyltetrahydroquinolines 3a-l.

Figure ESI 1. ¹H-NMR spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.






Figure ESI 2. ¹³C-NMR spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.**Figure ESI 3.** DEPT-135 spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.

Figure ESI 4. COSY spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.




Figure ESI 5. HSQC spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.






Figure ESI 6. HMBC spectrum of *cis*-4-Acetamido-6-acetyl-2-methyl-1,2,3,4-tetrahydroquinoline **3a**.**Figure ESI 7.** ¹H-NMR spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.



Figure ESI 8. ¹³C-NMR spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.**Figure ESI 9.** DEPT-135 spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.



Figure ESI 10. COSY spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.**Figure ESI 11.** HSQC spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.



Figure ESI 12. HMBC spectrum of *cis*-4-Acetamido-2-methyl-1,2,3,4-tetrahydroquinoline **3b**.**Figure ESI 13.** ¹H-NMR spectrum of *cis*-4-Acetamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3c**.



Figure ESI 14. ¹³C-NMR spectrum of *cis*-4-Acetamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3c**.**Figure ESI 15.** DEPT-135 spectrum of *cis*-4-Acetamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3c**.



Figure ESI 16. ¹H-NMR spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.**Figure ESI 17.** ¹³C-NMR spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.

Figure ESI 18. DEPT-135 spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.




Figure ESI 19. COSY spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.




Figure ESI 20. HSQC spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.




Figure ESI 21. HMBC spectrum of *cis*-4-Acetamido-6-carboxy-2-methyl-1,2,3,4-tetrahydroquinoline **3d**.






Figure ESI 22. ¹H-NMR spectrum of *cis*-6-Acetyl-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3e**.**Figure ESI 23.** ¹³C-NMR spectrum of *cis*-6-Acetyl-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3e**.



Figure ESI 24. DEPT-135 spectrum of *cis*-6-Acetyl-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3e**.**Figure ESI 25.** ¹H-NMR spectrum of *cis*-4-Formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3f**.



Figure ESI 26. ¹³C-NMR spectrum of *cis*-4-Formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3f**.**Figure ESI 27.** DEPT-135 spectrum of *cis*-4-Formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3f**.



Figure ESI 28. ¹H-NMR spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.**Figure ESI 29.** ¹³C-NMR spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.



Figure ESI 30. DEPT-135 spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.**Figure ESI 31.** COSY spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.

Figure ESI 32. HSQC spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.




Figure ESI 33. HMBC spectrum of *cis*-4-Formamido-6-methoxy-2-methyl-1,2,3,4-tetrahydroquinoline **3g**.






Figure ESI 34. ¹H-NMR spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.**Figure ESI 35.** ¹³C-NMR spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.



Figure ESI 36. DEPT-135 spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.**Figure ESI 37.** COSY spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.

Figure ESI 38. HSQC spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.




Figure ESI 39. HMBC spectrum of *cis*-6-Carboxy-4-formamido-2-methyl-1,2,3,4-tetrahydroquinoline **3h**.






Figure ESI 40. ¹H-NMR spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.**Figure ESI 41.** ¹³C-NMR spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.

Figure ESI 42. DEPT-135 spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.




Figure ESI 43. NOESY spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.




Figure ESI 44. COSY spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.




Figure ESI 45. HSQC spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.






Figure ESI 46. HMBC spectrum of *cis*-6-Acetyl-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3i**.**Figure ESI 47.** ¹H-NMR spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.



Figure ESI 48. ¹³C-NMR spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.**Figure ESI 49.** DEPT-135 spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.

Figure ESI 50. COSY spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.




Figure ESI 51. HSQC spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.






Figure ESI 52. HMBC spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3j**.**Figure ESI 53.** ¹H-NMR spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.



Figure ESI 54. ¹³C-NMR spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.**Figure ESI 55.** DEPT-135 spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.

Figure ESI 56. COSY spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.




Figure ESI 57. HSQC spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.






Figure ESI 58. HMBC spectrum of *cis*-6-Methoxy-4-(pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3k**.**Figure ESI 59.** ¹H-NMR spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3l**.



Figure ESI 60. ¹³C-NMR spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **31**.**Figure ESI 61.** DEPT-135 spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **31**.

Figure ESI 62. COSY spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3I**.




Figure ESI 63. HSQC spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3I**.




















Figure ESI 64. HMBC spectrum of *cis*-4-(Pyrrolidinyl-2-one)-2-methyl-1,2,3,4-tetrahydroquinoline **3l**.






4. Photographic records of the phenotypic changes during the development of the zebrafish embryo treated with compounds 3a-l after 96 hpf.






Compound	Concentration in μM (96 hpf)			
	Control		75	
 3a			75	
	150		50	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 351.2 \pm 5.7	100		25	





Compound	Concentration in μM (96 hpf)			
 3b	Control		100	
	LC ₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 223.8 \pm 7.1	150		50





Compound	Concentration in μM (96 hpf)			
 3c	Control		75	
	LC ₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 400.4 \pm 7.2	200		50





Compound	Concentration in μM (96 hpf)			
 3d	Control		200	
	400		125	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 429.7 \pm 0.3	250		62	






Compound	Concentration in μM (96 hpf)			
 3e	Control		100	
	125		31	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 429.3 \pm 0.4				






Compound	Concentration in μM (96 hpf)			
 3f	Control		100	
	150		75	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 216.0 \pm 7.1				





Compound	Concentration in μM (96 hpf)			
 3g	Control		200	
	LC ₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 435.9 \pm 3.7	250		125

Compound	Concentration in μM (96 hpf)			
 3h	Control		200	
	LC ₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 449.2 \pm 10.2	250		125

Compound	Concentration in μM (96 hpf)			
 3i	Control		75	
	LC ₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 426.3 \pm 7.0	100		50

Compound	Concentration in μM (96 hpf)			
 3j	Control		100	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 330.7 \pm 13.7	200		75	

Compound	Concentration in μM (96 hpf)			
 3k	Control		18	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 94.9 \pm 3.7	25		10	

Compound	Concentration in μM (96 hpf)			
 3l	Control		150	
LC₅₀ ($\mu\text{mol/L} \pm \text{SEM}$) 358.4 \pm 9.0	200		100	